IDEAYA Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IDYA Nasdaq 2836 www.ideayabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development - Sep 28th, 2026 4:00 am
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts - Sep 27th, 2026 7:25 pm
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 25th, 2026 4:00 am
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? - Sep 25th, 2026 3:42 am
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - Sep 9th, 2026 4:00 am
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - Sep 1st, 2026 4:00 am
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - Aug 31st, 2026 4:00 am
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - Aug 19th, 2026 4:00 am
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Aug 5th, 2026 2:12 pm
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 4th, 2026 4:00 am
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - Jul 27th, 2026 4:00 am
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - Jul 17th, 2026 7:00 am
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - Jun 17th, 2026 4:00 am
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers - Jun 15th, 2026 4:00 am
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Jun 11th, 2026 4:20 am
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Jun 9th, 2026 7:29 am